Rabey JM - Search Results

1

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group. Rabey JM, et al. Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30. doi: 10.1097/00002826-200011000-00005. Clin Neuropharmacol. 2000. PMID: 11575866 Clinical Trial.

2

Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis.

Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Klein C, et al. Among authors: rabey jm. Clin Neuropharmacol. 2006 Jul-Aug;29(4):215-9. doi: 10.1097/01.WNF.0000228176.98582.93. Clin Neuropharmacol. 2006. PMID: 16855423 Clinical Trial.

3

Clozapine in Parkinson's disease psychosis: 5-year follow-up review.

Klein C, Gordon J, Pollak L, Rabey JM. Klein C, et al. Among authors: rabey jm. Clin Neuropharmacol. 2003 Jan-Feb;26(1):8-11. doi: 10.1097/00002826-200301000-00003. Clin Neuropharmacol. 2003. PMID: 12567158

4

Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading.

Rabey JM, Klein C, Molochnikov A, Van Hilten B, Krauss P, Bonuccelli U. Rabey JM, et al. Clin Neuropharmacol. 2002 Mar-Apr;25(2):83-8. doi: 10.1097/00002826-200203000-00005. Clin Neuropharmacol. 2002. PMID: 11981234

5

Electroencephalographic findings with low-dose clozapine treatment in psychotic Parkinsonian patients.

Neufeld MY, Rabey JM, Orlov E, Korczyn AD. Neufeld MY, et al. Among authors: rabey jm. Clin Neuropharmacol. 1996 Feb;19(1):81-6. doi: 10.1097/00002826-199619010-00007. Clin Neuropharmacol. 1996. PMID: 8867521 Clinical Trial.

6

Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Van Sauten W, Van Hilten B. Rabey JM, et al. Clin Neuropharmacol. 1997 Aug;20(4):322-37. Clin Neuropharmacol. 1997. PMID: 9260730 Clinical Trial.

7

Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.

Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Rabey JM, et al. Clin Neuropharmacol. 1994 Jun;17(3):286-93. doi: 10.1097/00002826-199406000-00008. Clin Neuropharmacol. 1994. PMID: 9316674 Clinical Trial.

8

Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.

Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, Schechtman E, Korczyn AD. Inzelberg R, et al. Among authors: rabey jm. Neurology. 1996 Sep;47(3):785-8. doi: 10.1212/wnl.47.3.785. Neurology. 1996. PMID: 8797480 Clinical Trial.

9

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Rabey JM, et al. Mov Disord. 2007 Feb 15;22(3):313-8. doi: 10.1002/mds.21116. Mov Disord. 2007. PMID: 17034006 Clinical Trial.

10

The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.

Rabey JM, Streifler M, Treves T, Korczyn AD. Rabey JM, et al. Adv Neurol. 1990;53:451-5. Adv Neurol. 1990. PMID: 2122652 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

148 results

Search Page

Filters